The phosphatase 2A (PP2A) is one of the major cellular serine-threonine phosphatases. It was recently shown that the gene encoding for the b isoform of its subunit A, PPP2R1B, is altered in human lung and colorectal carcinomas, suggesting a role in human tumorigenesis. Here, we report the detection of mutations in breast, lung carcinomas and melanomas in the genes of both a (PPP2R1A) and b isoforms. Mutations aecting PPP2R1B were found in four breast carcinomas, while mutations in PPP2R1A were found in carcinomas of the breast and of the lung and in one melanoma. Most of the mutations aecting PPP2R1B were exons deletions, suggesting abnormal splicing. These splicing abnormalities were detected in tumor samples in the absence of the normal splicing product, and were not found in several normal controls. In one case, a homozygous deletion present in tumor DNA, and not in the matched normal control was demonstrated. Mutations aecting the PPP2R1A gene were nucleotide substitutions changing highly conserved amino acids and one frame-shift. Although the frequency of alterations is low, the inclusion of both isoforms of subunit A in the genes mutated in human cancer and the addition of breast cancer to the list of neoplasms in which PPP2R1B is altered, strengthen the potential role of PP2A in human tumorogenesis.
Introduction
The phosphatase 2A (PP2A) is one of the major cellular serine-threonine phosphatases (Wera and Hemmings, 1995) . The holoenzyme consists of heterotrimeric forms generated by the association of a 36 kDa catalytic subunit C and a 65 kDa structural subunit A with over 15 dierent subunits B, that probably in¯uence substrate speci®city and/or subcellular localization. The subunit A forms the scaold of the holoenzyme and exists in two isoforms, a and b, which share 86% amino acid identity and are encoded by dierent genes (Hemmings et al., 1990) . Isoform a consists of 590 amino acids and isoform b of 602 amino acids. Comparison of primary amino acid sequence reveals a high degree of conservation of both subunit A isoforms from yeast to man. The PPP2R1A gene encodes the a isoform and PPP2R1B the b isoform.
Various indications suggested a role of PP2A in tumorigenesis. PP2A is involved in the regulation of various cellular pathways, including control of cell growth (Walter and Mumby, 1993; Wera and Hemmings, 1995) . It is also noteworthy that the subunit A physically interacts with some viral tumor proteins, including the small T antigens of the papovaviruses SV40 and polyoma, and the middle t antigen of polyoma (Walter et al., 1990; Yang et al., 1991) , suggesting a mechanism of viral tumorigenesis involving the inactivation of PP2A via displacement of physiological interacting proteins by viral tumor antigens. A dierent mechanism involving the phosphatase PP2A in viral tumorigenesis was demonstrated by the loss of enzymatic activity caused by phosphorylation at Tyr-307 of the catalitic subunit C by the tyrosine kinase p60 v-src (Chen et al., 1992 (Chen et al., , 1994 . The recent ®nding of inactivating mutations in the PPP2R1B gene in lung and colon carcinomas indicates a role of PP2A in human tumorigenesis through a mechanism of functional inactivation (Wang et al., 1998) .
Since various subunits and/or isoforms participate to the constitution of the fully active enzyme, it seems possible that alterations aecting dierent subunits or isoforms may have the same functional eect on phosphatase function and may promote tumorigenesis. Here, we describe a mutation detection study carried out in breast, lung and melanoma primary tumors and cell lines, that testify that both isoforms a and b of the subunit A may play a role in tumorigenesis.
SSCP analysis of PPP2R1A revealed four abnormal patterns, one in the melanoma 11M, another in the lung cancer 16L and two in the breast cancers BCR16 and BCR38. Sequence analysis of the PCR products revealed nucleotide changes causing amino acid substitutions and a frame-shift mutation (Figure 1 ). Three amino acid substitutions, Glu-64 to Asp in the lung carcinoma, Arg-418 to Trp in the melanoma cell line, and Glu-64 to Gly in the breast cancer BCR16 change highly conserved amino acids. These positions are in fact phylogenetically conserved in both a and b isoforms from yeast to man, suggesting that these amino acid substitutions are not neutral polymorphisms and may aect protein function, possibly leading to abnormal PP2A phosphatase activity. The fourth change was an insertion of a T at nucleotide 652 causing a frame-shift mutation starting at amino acid 170 in the breast cancer BCR38.
In the PPP2R1B gene, the few identi®ed SSCP shifts were likely to represent rare polymorphisms (data not shown). An A-1778 transition to G was found in the breast cancer cell line BT20, which does not change the encoded amino acid. A transition of nucleotide G-298 to A, which changes the amino acid glycine-90 into aspartic acid, was found in seven breast and one lung tumor samples. Although this latter change was previously reported as a mutation aecting three lung carcinomas (Wang et al., 1998) , our results do not support this conclusion. Furthermore, the glycine-90 residue is not phylogenetically conserved, suggesting that this substitution is likely to represent a nonpathogenetic polymorphism. Functional studies will be necessary to evaluate the signi®cance of this change.
Besides abnormal SSCP patterns, internal deletions of PPP2R1B RNA ± PCR products were detected in various tumor samples. Long range PCRs detected four samples (BCR 8, 21, 33 and 38) with products shorter than normal, indicating the absence of segments from the mature PPP2R1B RNA ( Figure  2 ). Sequence analysis determined that abnormal RNA is caused by the precise deletion of exon 9. The removal of exon 9 determines the deletion of 45 amino acids. This change was also detected by Wang et al. (1998) in two non-small cell lung carcinomas (T9 and T12). Although the reading frame is not aected, this deletion is predicted to produce a subunit A unable to associate with the regulatory subunit B (Ruediger et al., 1994) . Analysis of genomic DNAs with primers that amplify individual exons (Figure 3 ), revealed that exon 9 is homozygously deleted in sample BCT33, thus explaining its absence in the mature mRNA of this tumor sample. This alteration was found only in tumor DNA and not in the matched normal DNA of the same patient, indicating a somatic event in the generation of this deletion. No apparent sequence alterations were detected in the other three samples that could explain the absence of exon 9 in mature mRNA.
Discussion
Our results indicate that PPP2R1A and PPP2R1B are altered in human neoplasms at low frequency. Together with a previous report, which indicated the presence of mutations aecting the PPP2R1B gene in lung and colon carcinomas (Wang et al., 1998) , our results strengthen the postulated role of PP2A in human tumorigenesis via a mechanism of inactivation of the phosphatase activity. Moreover, the ®nding of mutations aecting both isoform of the phosphatase 2A subunit A suggests that additional subunits might also be altered in tumor samples, producing the same or similar eect on phosphatase activity.
Various functions are associated with the phosphatase 2A. This enzyme modulates the activity of phosphorylase B kinase, casein kinase 2, mitogenstimulated S6 kinase, and MAP-2 kinase, which in turn aect a variety of cellular processes, including cell cycle progression, whose alteration may be involved in Figure 1 Mutations of PPP2R1A. Sequence chromatograms show the presence of nucleotide changes leading to amino acid substitutions in samples 16L, 10M and BCR16 and a frameshift in sample BCR38 tumorigenesis. Various evidences linking the phosphatase 2A to the tumorigenic process are intriguing. For example, the catalitic subunit of PP2A can be phosphorylated in vitro and in vivo by the oncogene p60 v-src at Tyr-307, leading to 90% loss of activity (Chen et al., 1992 (Chen et al., , 1994 . It was also shown that the PP2A heterotrimer containing the regulatory B56 subunit could down-regulate the cellular level of bcatenin (Seeling et al., 1999) . Excess of b-catenin is tumorigenic, as demonstrated by mutations in APC or in the b-catenin phosphorylation site in colon, pancreatic, hepatic and skin cancers, which resulted in insucient degradation of b-catenin (Sparks et al., 1998) . It is conceivable that mutations in the subunit A, which aect the function of the holoenzyme PP2A, may also lead to an increase in the amount of b-catenin whose level may become critical for tumorigenesis.
Mutations in the isoforms PPP2R1A or PPP2R1B may aect the interaction with the other PP2A subunits. It has been shown that the a-isoform forms a structure that consists entirely of helices and connecting loops, whose removal or mutations may aect interaction with the subunits C or B (Ruediger et al., 1994) . The high degree of homology suggests that the b isoform has a similar, if not identical, structure and function. It is interesting to note that the interaction of the tumor antigens SV40 small T and polyoma small and middle T, abolishes the interaction of the A subunit with the regulatory B subunit, possibly leading to phosphatase inactivation with a mechanism mimicking the inactivation of P53 and RB1 caused by SV40 large-T antigen. It was also shown that the interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the MAP kinase pathway and induces cell proliferation (Sontag et al., 1993) . Similarly, deletion of exon 9, the most frequent type of mutation detected in PPP2R1B so far, removes the homologous isoform a helix 9, whose absence abolishes the binding to the B regulatory subunit (Ruediger et al., 1994) . This result indicates that the absence of exon nine, although it does not produce a frame-shift mutation, it is likely to produce a non functional phosphatase enzyme because it is unable to interact with the regulatory B subunit.
The gene for PPP2R1B is located at chromosome 11 band q23. LOH at this region is observed in 30 ± 50% of breast, lung, ovary, cervical carcinomas and melanomas, and in 10 ± 15% of non-Hodgin's lymphomas and chronic lymphocytic leukemias (Davis et al., 1996; DoÈ hner et al., 1997; Gabra et al., 1996; Hampton et al., 1994a,b; Herbst et al., 1995; Iizuka et al., 1995; Negrini et al., 1995; Rasio et al., 1995) . At least two subregions, the LOH region 1 and 2, respectively located at 11q23.1 and 11q23.3 were found to be independently deleted in human breast cancer . PPP2R1B was mapped at 11q23.1 between loci D11S1347 and D11S927 (Baysal et al., 1998) , which coincides with the re®ned LOH region 1 (DiIasio et al., 1999), suggesting that PPP2R1B may represent the tumor suppressor gene located in this subregion of LOH. Nevertheless, this ®nding does not end the search for tumor suppressor genes at chromosome 11q23. In fact, LOH studies suggested the possibility that chromosome 11q harbors more than one tumor-associated gene altered and inactivated in human malignancies, as indicated by the ®nding of up to ®ve dierent regions of LOH at 11q22-q25 (Kerangueven et al., 1997) . Indeed, mutations in ATM were found in hematopoietic T and B cell malignancies, but not in solid tumors Vorechovsky et al., 1996 Vorechovsky et al., , 1997 . The putative tumor suppressor gene PGL1 involved in the paraganglyoma (Baysal et al., 1998) , a rare cancer predisposing Figure 3 Homozygous deletion of exon 9 in the breast cancer BCT33. Exons 8, 9 and 10 of the gene were ampli®ed using described oligonucleotides (Baysal et al., 1998) . A 123 bp ladder (LifeSciences) was used as marker (m). The other samples are: N, normal DNA of sample BCT33; T, tumor DNA of sample BCT33; P, positive control consisting of normal DNA from an unrelated sample; B, blank disorder presenting mostly benign tumors of the head and neck whose locus maps at 11q23, is still elusive. Moreover, the ®nding of mutations in subunits A of PP2A in less than 10% of tested solid tumors does not account for the frequencies of LOH detected at 11q23, which range from 30 ± 50%, further supporting the existence of other putative tumor recessive genes in the region. All these data indicate that chromosome region 11q23 harbors, in addition to PPP2R1B and ATM, other genes involved in tumorigenesis. Their identi®ca-tion and characterization of their role in human tumorigenesis are not yet completed.
On the basis of the mapping of the expressed sequence tag SHGC-8081, the PPP2R1A gene maps on the long arm chromosome 19 between loci D19S867 and D19S572. Loss of heterozygosity studies have indicated the long arm of chromosome 19 as the location of a putative tumor suppressor gene involved in human gliomas. PPP2R1A, however, maps between loci D19S412 and STD, which are telomeric to the re®ned region of deletion (Rosenberg et al., 1996) , possibly indicating the presence of more than one tumor recessive gene in the region.
The ubiquitous expression of the phosphatase 2A together with the detection of mutations in various types of human tumor samples, suggest that both PPP2R1A and PPP2R1B genes may be tumor suppressor genes involved in a variety of human solid tumors. Mutations aecting these two genes have been found in lung, breast and colon carcinoma but many other solid tumors, including cervical, ovarian, gastric and nasopharyngeal carcinomas, frequently aected by deletions at the same 11q23 region, may also be aected by mutations in this gene. Furthermore, since PPP2R1A and PPP2R1B mutations result in the inactivation of PP2A function, it seems possible that alterations of other subunits of the PP2A holoenzyme might also be associated with the tumorigenic process.
This ®nding could open new areas of investigation for cancer diagnosis and therapy.
Materials and methods

Cell lines, DNA and RNA samples
The following cell lines were used in the course of the study: 13 breast carcinomas (BT20, BT474, BT549, HBL100, MCF7, MDA-MB-175, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-436, MDA-MB-453, SK-BR-3, T-47D), 12 lung carcinomas (Ca-Lu-6, SK-LU-1, A549, SK-MES-1, H446, H69, H146, H592, H460, CALV1, CALV3, POVD) and 14 melanomas derived from primary tumors. Primary tumor samples were an unselected series of lung carcinomas collected at the Istituto Nazionale Tumori, Milano, Italy, and an unselected series of breast carcinomas collected at the Karolinska Institute, Huddinge, Sweden. Genomic DNA was puri®ed from cell pellets using standard Hirt's/ProteinaseK lysis followed by organic extractions and ethanol/NaCl precipitation (Maniatis et al., 1982) . RNA was puri®ed from cell pellets using the RNA-Stat30 reagent (TelTest Inc., Friendswood, TX, USA).
PCR ± SSCP and sequencing PPP2R1B gene was analysed by RT ± PCR ± SSCP. cDNAs were produced by reverse transcription of 1 mg of total RNA with SuperscriptII (Life Technologies) primed by oligo-dT and random primers in 20 ml. One ml was used for PCR ampli®cation. PCR reactions were carried out with 1.0 mM of each primer, 20 mM each of dATP, dGTP and dTTP, 2 mM of dCTP, 0.5 mCi per reaction of [a-32 P]dCTP (3000 Ci/mmol, Amersham), 1.5 mM MgCl2, 10 mM TrisHCl (pH 8.3), 50 mM KCl, 0.01% gelatin, 12.5% glycerol and 0.5 units of Taq polymerase (Perkin-Elmer Cetus) in a volume of 10 ml. The initial denaturation step was for 4 min at 948C. PCR ampli®cation was carried out for 30 cycles with a denaturing step at 948C for 15 s, annealing for 30 s at 578C, and extension at 728C for 30 s. The SSCP analysis was performed essentially as described (Hayashi, 1996) . PCR products were separated on 0.56 non-denaturing Mutation Detection Enhanced matrix gels (FMC Bioproducts, Rockland, MA, USA) and visualized by autoradiography. cDNA segments exhibiting band shifts were reampli®ed using the same conditions. The PCR products were separated in a 2% agarose gel in 0.56 Tris-borate EDTA buer, gel puri®ed and sequenced. Sequence analysis was carried out in an automated sequencing station Applied Biosystem model 377, using the dye terminator chemistry. Both strands were sequenced using cDNA speci®c oligonucleotide primers. Nucleotide sequences were analysed using the Wisconsin (GCG) program package version Unix-8.1. The DNA exons of the PPP2R1B gene were ampli®ed using described oligonucleotides (Baysal et al., 1998) . Oligonucleotides for amplifying PPP2R1A or PPP2R1B cDNA segments are shown in Tables 1 and 2. 
